Advertisement
Research Article

The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites

  • Michael Delves,

    Affiliation: Department of Life Sciences, Imperial College London, London, United Kingdom

    X
  • David Plouffe,

    Affiliation: Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Christian Scheurer,

    Affiliations: Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Stephan Meister,

    Affiliation: The Scripps Research Institute, La Jolla, California, United States of America

    X
  • Sergio Wittlin,

    Affiliations: Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Elizabeth A. Winzeler,

    Affiliations: Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America, The Scripps Research Institute, La Jolla, California, United States of America

    X
  • Robert E. Sinden,

    Affiliation: Department of Life Sciences, Imperial College London, London, United Kingdom

    X
  • Didier Leroy mail

    leroyd@mmv.org

    Affiliation: Medicines for Malaria Venture, Geneva, Switzerland

    X
  • Published: February 21, 2012
  • DOI: 10.1371/journal.pmed.1001169

About the Authors

Michael Delves, Robert E. Sinden
Department of Life Sciences, Imperial College London, London, United Kingdom
David Plouffe, Elizabeth A. Winzeler
Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
Christian Scheurer, Sergio Wittlin
Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland
Christian Scheurer, Sergio Wittlin
University of Basel, Basel, Switzerland
Stephan Meister, Elizabeth A. Winzeler
The Scripps Research Institute, La Jolla, California, United States of America
Didier Leroy
Medicines for Malaria Venture, Geneva, Switzerland

Corresponding Author

Email: leroyd@mmv.org

Competing Interests

EW owns Novartis stock and receives compensation from Novartis. Some of the compounds which are contained in products sold by Novartis to treat malaria (e.g., coartem) are profiled herein. DL is employed by MMV but has no influence at all on the decision for funding a project. Indeed, such a decision is taken based on the recommendations of an independent External Scientific Advisory Committee. All other authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: MD RES SW EAW. Performed the experiments: MD DP SM CS. Analyzed the data: MD CS RES SW DP EAW DL. Wrote the first draft of the manuscript: DL. Contributed to the writing of the manuscript: RES DL. ICMJE criteria for authorship read and met: MD DP CS SM SW EAW RES DL. Agree with manuscript results and conclusions: MD DP CS SM SW EAW RES DL.